Drug intelligence / Profile preview

autologous dendritic cell vaccine + ny-eso-1 + alpha-galactosylceramide

Development stage: Unknown
Lead developer: Malaghan Institute of Medical Research
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous, Intradermal

Overview

This autologous dendritic cell vaccine is a personalized cancer immunotherapy developed by the Malaghan Institute of Medical Research. It consists of a patient's own monocyte-derived dendritic cells loaded with peptides from the NY-ESO-1 cancer-testis antigen and the NKT cell agonist alpha-galactosylceramide (α-GalCer). The vaccine is designed to stimulate a robust anti-tumor immune response by presenting NY-ESO-1 to T cells while simultaneously activating type 1 Natural Killer T (NKT) cells via the α-GalCer adjuvant. It has been investigated in Phase I and Phase II clinical trials as an adjuvant treatment for patients with high-risk, surgically resected stage II–IV cutaneous melanoma to prevent recurrence.

Other names: NY-ESO-1/alpha-GalCer-loaded DC vaccineNY-ESO-1/alpha-galactosylceramide-loaded dendritic cell vaccine

Targets

NY-ESO-1 (New york esophageal squamous cell carcinoma 1)CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)

Beyond the preview

Go deeper on autologous dendritic cell vaccine + ny-eso-1 + alpha-galactosylceramide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous dendritic cell vaccine + ny-eso-1 + alpha-galactosylceramide.

Explore the full profile